NasdaqCM:ABEO
NasdaqCM:ABEOBiotechs

Abeona Therapeutics (ABEO) Is Up 17.9% After ZEVASKYN Wins Permanent J-Code and Narrows Net Loss – Has The Bull Case Changed?

Abeona Therapeutics recently reported a third-quarter 2025 net loss of US$5.16 million, a significant improvement from US$30.27 million a year earlier, as its efforts to commercialize ZEVASKYN for RDEB patients advance alongside expanded treatment center access. A pivotal development includes the Centers for Medicare and Medicaid Services establishing a permanent J-code for ZEVASKYN, poised to support broader reimbursement and access from January 2026. With a 17.90% weekly and 18.47% daily...
NasdaqGS:OTTR
NasdaqGS:OTTRElectric Utilities

What Otter Tail (OTTR)'s Dividend Hike and Upgraded Earnings Outlook Mean for Shareholders

On November 3, 2025, Otter Tail Corporation's board declared a quarterly dividend of US$0.525 per share, payable on December 10, 2025, and raised its full-year 2025 diluted earnings guidance to US$6.32–US$6.62 per share after announcing third-quarter results. This guidance increase signals management's confidence in operational prospects, despite a year-over-year decline in third-quarter earnings per share. We'll assess how Otter Tail's increased 2025 earnings outlook affects the company's...